All News
Deucravacitinib and Renal Function: Insights from the PAISLEY Trial
In the phase 2 PAISLEY trial, deucravacitinib met its primary and secondary endpoints, demonstrating efficacy across multiple clinical and patient-reported outcomes. However, the impact on renal function has remained unclear. An abstract presented at ACR provides new insights.
Read Article
Do Patients with Rheumatic Diseases 'Weather' the Storm?
Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #acr25.
https://t.co/rY3T6tWsgu https://t.co/vdgT2DB5lH
Dr. John Cush RheumNow ( View Tweet)
Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention
At #ACR25, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological https://t.co/OIgh8JQsFa
Dr. John Cush RheumNow ( View Tweet)
The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE
Lupus nephritis affects almost half of patients with SLE and conveys a mortality rate of up to 30% at 10 years, with at least 10-22% of patients developing end-stage kidney disease. Early detection and diagnosis are https://t.co/ggoA2KsqXg
Dr. John Cush RheumNow ( View Tweet)
Belimumab Before or After Immunosuppressant
Dr. Yuz Yusof reports on abstract 0803 presented at #ACR25
https://t.co/BVFhDDfTvW https://t.co/F9ZvGXIqVn
Dr. John Cush RheumNow ( View Tweet)
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?
Despite major advances in RA management, some patients develop difficult-to-treat RA (D2TRA), characterized by ongoing inflammation and impairment despite multiple therapies. While understanding of the https://t.co/FcF0V82KdT
Dr. John Cush RheumNow ( View Tweet)
The Long View of Diagnostic Delay in Axial Spondyloarthritis
At #ACR25, Abstract #1407 presented a cross-sectional analysis from the Brazilian Spondyloarthritis Registry (RBE), offering a unique perspective on how diagnostic patterns have evolved over six decades. https://t.co/7ttYXJtfpc
Dr. John Cush RheumNow ( View Tweet)
PsA: Impact of Sex
Dr. Arthur Kavanaugh highlights the importance of sex on disease characteristics and response to therapy in psoriatic arthritis, reporting from #ACR25.
https://t.co/QtU4iATexR https://t.co/uCJsxYpFTc
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Best Abstracts - Day 2
After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.
https://t.co/gyIWQXVJ50 https://t.co/vjlK41hzFD
Links:
Dr. John Cush RheumNow ( View Tweet)
🌟 Wonderful news! One of the EMEUNET Top 10 Abstracts ACR 2025 has been accepted on Rheumatology!
🎊 Congratulations Erdem Bektas (@ebektasmd ) for this achievement!
👉You can read the manuscript in this link: https://t.co/teEscaBVG3
#EMEUNET https://t.co/BKRXTXiQ8U
Links:
EMEUNET EMEUNET ( View Tweet)
Should we be using JAKi more in female SpA patients?
In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of https://t.co/smLao0q2hv
Dr. John Cush RheumNow ( View Tweet)
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults
In RA alone, nearly 40% of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental https://t.co/2pqXGURQtL
Dr. John Cush RheumNow ( View Tweet)
Early Peripheral SpA: Is it okay to stop treatment sometimes?
Dr. Richard Conway reports on abstract 0568 "Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial," presented at #ACR25
https://t.co/FtI2o90v9O https://t.co/jUAEDZhDW5
Dr. John Cush RheumNow ( View Tweet)
Is Low Disease Activity Low Enough?
Drs. Jonathan Kay and Joel Kremer discuss abstract 0449, "Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life". #ACR25 https://t.co/kI8qOYjVL4
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3
Dr. John Cush RheumNow ( View Tweet)
Hospitalization in Stills: Is it "Still" an infection?
Dr. Janet Pope discusses abstract 0163, "Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)," https://t.co/3Z0U9XN3nx
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid arthritis and the ‘big bang’ at #ACR25!
Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?
https://t.co/QDvdiP3q9R https://t.co/cz4j4vZkSd
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g
@synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
From Fitbit to first diagnosis: AI is rewriting the RA playbook
Two studies presented at this year’s #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://t.co/8AwBZkyZIW
Dr. John Cush RheumNow ( View Tweet)
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases
At #ACR25, the ACR presented new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, https://t.co/nJjtTMHnD3
Dr. John Cush RheumNow ( View Tweet)
